Why Celldex Therapeutics Stock Is Skyrocketing Today
Shares of Celldex Therapeutics (NASDAQ: CLDX) were skyrocketing 28.4% as of 10:47 a.m. EDT on Monday. The big jump came after the company announced positive data from its ongoing phase 1b clinical study evaluating CDX-0159 in treating two of the most common types of hives.
With the huge gain for the biotech stock today, you'd expect Celldex's phase 1b clinical results to be really great. And they were.
The company said that 18 of the 19 patients who received a single full dose of CDX-0159 experienced a complete response. The other patient in the group had a "marked partial response," according to the company.
Source Fool.com
